FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2396543304> ?p ?o ?g. }

• W2396543304 endingPage "2079" @default.
• W2396543304 startingPage "2079" @default.
• W2396543304 abstract "Very preterm infants are at risk of developing encephalopathy of prematurity and long-term neurodevelopmental delay. Erythropoietin treatment is neuroprotective in animal experimental and human clinical studies.To determine whether prophylactic early high-dose recombinant human erythropoietin (rhEPO) in preterm infants improves neurodevelopmental outcome at 2 years' corrected age.Preterm infants born between 26 weeks 0 days' and 31 weeks 6 days' gestation were enrolled in a randomized, double-blind, placebo-controlled, multicenter trial in Switzerland between 2005 and 2012. Neurodevelopmental assessments at age 2 years were completed in 2014.Participants were randomly assigned to receive either rhEPO (3000 IU/kg) or placebo (isotonic saline, 0.9%) intravenously within 3 hours, at 12 to 18 hours, and at 36 to 42 hours after birth.Primary outcome was cognitive development assessed with the Mental Development Index (MDI; norm, 100 [SD, 15]; higher values indicate better function) of the Bayley Scales of Infant Development, second edition (BSID-II) at 2 years corrected age. The minimal clinically important difference between groups was 5 points (0.3 SD). Secondary outcomes were motor development (assessed with the Psychomotor Development Index), cerebral palsy, hearing or visual impairment, and anthropometric growth parameters.Among 448 preterm infants randomized (mean gestational age, 29.0 [range, 26.0-30.9] weeks; 264 [59%] female; mean birth weight, 1210 [range, 490-2290] g), 228 were randomized to rhEPO and 220 to placebo. Neurodevelopmental outcome data were available for 365 (81%) at a mean age of 23.6 months. In an intention-to-treat analysis, mean MDI was not statistically significantly different between the rhEPO group (93.5 [SD, 16.0] [95% CI, 91.2 to 95.8]) and the placebo group (94.5 [SD, 17.8] [95% CI, 90.8 to 98.5]) (difference, -1.0 [95% CI, -4.5 to 2.5]; P = .56). No differences were found between groups in the secondary outcomes.Among very preterm infants who received prophylactic early high-dose rhEPO for neuroprotection, compared with infants who received placebo, there were no statistically significant differences in neurodevelopmental outcomes at 2 years. Follow-up for cognitive and physical problems that may not become evident until later in life is required.clinicaltrials.gov Identifier: NCT00413946." @default.
• W2396543304 created "2016-06-24" @default.
• W2396543304 creator A5006442525 @default.
• W2396543304 creator A5035275541 @default.
• W2396543304 creator A5048015577 @default.
• W2396543304 creator A5050426428 @default.
• W2396543304 creator A5053625034 @default.
• W2396543304 creator A5054631018 @default.
• W2396543304 creator A5078043213 @default.
• W2396543304 creator A5090402251 @default.
• W2396543304 date "2016-05-17" @default.
• W2396543304 modified "2023-10-13" @default.
• W2396543304 title "Effect of Early Prophylactic High-Dose Recombinant Human Erythropoietin in Very Preterm Infants on Neurodevelopmental Outcome at 2 Years" @default.
• W2396543304 cites W146111145 @default.
• W2396543304 cites W1488966948 @default.
• W2396543304 cites W1637157786 @default.
• W2396543304 cites W1969172610 @default.
• W2396543304 cites W1970086378 @default.
• W2396543304 cites W1972604478 @default.
• W2396543304 cites W1973509095 @default.
• W2396543304 cites W1992686641 @default.
• W2396543304 cites W1999784325 @default.
• W2396543304 cites W2016693709 @default.
• W2396543304 cites W2019549525 @default.
• W2396543304 cites W2020591797 @default.
• W2396543304 cites W2022167001 @default.
• W2396543304 cites W2031682804 @default.
• W2396543304 cites W2033237312 @default.
• W2396543304 cites W2034682648 @default.
• W2396543304 cites W2039070114 @default.
• W2396543304 cites W2043374149 @default.
• W2396543304 cites W2067292954 @default.
• W2396543304 cites W2088472932 @default.
• W2396543304 cites W2094541539 @default.
• W2396543304 cites W2097396554 @default.
• W2396543304 cites W2103702484 @default.
• W2396543304 cites W2105109183 @default.
• W2396543304 cites W2110230188 @default.
• W2396543304 cites W2121693179 @default.
• W2396543304 cites W2125879679 @default.
• W2396543304 cites W2128346216 @default.
• W2396543304 cites W2133369864 @default.
• W2396543304 cites W2149763277 @default.
• W2396543304 cites W2151085630 @default.
• W2396543304 cites W2153203681 @default.
• W2396543304 cites W2160720400 @default.
• W2396543304 cites W2168946139 @default.
• W2396543304 cites W2345511416 @default.
• W2396543304 cites W3148465273 @default.
• W2396543304 cites W73228081 @default.
• W2396543304 doi "https://doi.org/10.1001/jama.2016.5504" @default.
• W2396543304 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27187300" @default.
• W2396543304 hasPublicationYear "2016" @default.
• W2396543304 type Work @default.
• W2396543304 sameAs 2396543304 @default.
• W2396543304 citedByCount "103" @default.
• W2396543304 countsByYear W23965433042016 @default.
• W2396543304 countsByYear W23965433042017 @default.
• W2396543304 countsByYear W23965433042018 @default.
• W2396543304 countsByYear W23965433042019 @default.
• W2396543304 countsByYear W23965433042020 @default.
• W2396543304 countsByYear W23965433042021 @default.
• W2396543304 countsByYear W23965433042022 @default.
• W2396543304 countsByYear W23965433042023 @default.
• W2396543304 crossrefType "journal-article" @default.
• W2396543304 hasAuthorship W2396543304A5006442525 @default.
• W2396543304 hasAuthorship W2396543304A5035275541 @default.
• W2396543304 hasAuthorship W2396543304A5048015577 @default.
• W2396543304 hasAuthorship W2396543304A5050426428 @default.
• W2396543304 hasAuthorship W2396543304A5053625034 @default.
• W2396543304 hasAuthorship W2396543304A5054631018 @default.
• W2396543304 hasAuthorship W2396543304A5078043213 @default.
• W2396543304 hasAuthorship W2396543304A5090402251 @default.
• W2396543304 hasBestOaLocation W23965433041 @default.
• W2396543304 hasConcept C103728769 @default.
• W2396543304 hasConcept C118552586 @default.
• W2396543304 hasConcept C126322002 @default.
• W2396543304 hasConcept C142724271 @default.
• W2396543304 hasConcept C164953862 @default.
• W2396543304 hasConcept C168563851 @default.
• W2396543304 hasConcept C169900460 @default.
• W2396543304 hasConcept C1862650 @default.
• W2396543304 hasConcept C187212893 @default.
• W2396543304 hasConcept C204787440 @default.
• W2396543304 hasConcept C27081682 @default.
• W2396543304 hasConcept C2778376644 @default.
• W2396543304 hasConcept C2778534260 @default.
• W2396543304 hasConcept C2779083892 @default.
• W2396543304 hasConcept C2779234561 @default.
• W2396543304 hasConcept C2779421357 @default.
• W2396543304 hasConcept C42219234 @default.
• W2396543304 hasConcept C54355233 @default.
• W2396543304 hasConcept C66322754 @default.
• W2396543304 hasConcept C71924100 @default.
• W2396543304 hasConcept C86803240 @default.
• W2396543304 hasConceptScore W2396543304C103728769 @default.
• W2396543304 hasConceptScore W2396543304C118552586 @default.
• W2396543304 hasConceptScore W2396543304C126322002 @default.

• next